DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
968
4G7XH22
1
Antibody
Investigational
Unknown
Unknown
Leukemia; Lymphoma
Unknown
4G7XH22
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEDI-639
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MEDI-639
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CIRMTUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell
Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor
CIRMTUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
FEH7RQ7B3J
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AD-439
1
Antibody
Investigational
Unknown
Unknown
Unknown
Envelope polyprotein GP160 inhibitor
AD-439
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BUDIGALIMAB
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; HIV Infections; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma
Programmed cell death protein 1 inhibitor
BUDIGALIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
6VDO4TY3OO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CSL-360
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute
Interleukin-3 receptor subunit alpha inhibitor
CSL-360
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EZABENLIMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
EZABENLIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AFASEVIKUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Interleukin 17A inhibitor
AFASEVIKUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
TG8A3DSU6Z
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DUVORTUXIZUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
DUVORTUXIZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
J545GSE96Y
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CCR5MAB004
1
Antibody
Investigational
Unknown
Unknown
HIV Infections
C-C chemokine receptor type 5 inhibitor
CCR5MAB004
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SERCLUTAMAB TALIRINE
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
SERCLUTAMAB TALIRINE
×
Maximum Phase:
1
First Approval:
None
UNII:
7W0O278T12
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TEBOTELIMAB
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Hepatocellular; Endometrial Neoplasms; Stomach Neoplasms; Carcinoma, Squamous Cell
Lymphocyte activation gene 3 protein inhibitor
TEBOTELIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
L62556GPXB
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IDEC-159 111IN
1
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms
Tumor-associated antigen 72 binding agent
IDEC-159 111IN
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OCARATUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
B-lymphocyte antigen CD20 binding agent
OCARATUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
NTY9893GD0
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-1550
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RG-1550
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VULINACIMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
VULINACIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
SA09JNQ24D
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RO6895882
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RO6895882
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TB-403
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Placenta growth factor inhibitor
TB-403
×
Maximum Phase:
1
First Approval:
None
UNII:
46MVG4H2LF
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TIMOLUMAB
1
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Unknown
TIMOLUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
UJO03RO3K6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MLN-01
1
Antibody
Investigational
Unknown
Unknown
Unknown
Integrin beta-2 inhibitor
MLN-01
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HUM195
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HUM195
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
COFETUZUMAB PELIDOTIN
1
Antibody
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung
Unknown
COFETUZUMAB PELIDOTIN
×
Maximum Phase:
1
First Approval:
None
UNII:
249EAP69MT
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RAFIVIRUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Glycoprotein inhibitor
RAFIVIRUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
F6G4126BPE
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MDX-033
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MDX-033
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HUPAM4
1
Antibody
Investigational
Unknown
Unknown
Unknown
Mucin-1 binding agent
HUPAM4
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
14G2A
1
Antibody
Investigational
Unknown
Unknown
Epstein-Barr Virus Infections; Neuroblastoma
Disialoganglioside GD2 inhibitor
14G2A
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HUMAB 216
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
HUMAB 216
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TUCOTUZUMAB CELMOLEUKIN
1
Antibody
Investigational
Unknown
Unknown
Ovarian Neoplasms
Epithelial cell adhesion molecule other
TUCOTUZUMAB CELMOLEUKIN
×
Maximum Phase:
1
First Approval:
None
UNII:
4ON7FF680U
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NACOLOMAB TAFENATOX
1
Antibody
Investigational
Unknown
Unknown
Unknown
Trophoblast glycoprotein cross-linking agent
NACOLOMAB TAFENATOX
×
Maximum Phase:
1
First Approval:
None
UNII:
PRC47TA1NU
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PRITUMUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Vimentin other
PRITUMUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
Z6Q90D1G53
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZAMPILIMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
ZAMPILIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
52B38H09GZ
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PLAMOTAMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell
Unknown
PLAMOTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
5ENX424FNF
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MU-BC-1
1
Antibody
Investigational
Unknown
Unknown
Unknown
Fibronectin binding agent
MU-BC-1
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IDEC-159 90Y
1
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms
Tumor-associated antigen 72 binding agent
IDEC-159 90Y
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PG-110
1
Antibody
Investigational
Unknown
Unknown
Osteoarthritis, Knee
Beta-nerve growth factor inhibitor
PG-110
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
9
10
11
12
13
14
15
…
27
28
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA